These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29973205)

  • 1. Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
    Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
    Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
    Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
    Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X; Fraser M; Qiu Q; Tsang BK
    Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells.
    Woods DC; Alvarez C; Johnson AL
    Gynecol Oncol; 2008 Mar; 108(3):632-40. PubMed ID: 18191995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
    Wahl H; Tan L; Griffith K; Choi M; Liu JR
    Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of nuclear export inhibitors with potent anticancer activity in vivo.
    Mutka SC; Yang WQ; Dong SD; Ward SL; Craig DA; Timmermans PB; Murli S
    Cancer Res; 2009 Jan; 69(2):510-7. PubMed ID: 19147564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
    Liu X; Chong Y; Liu H; Han Y; Niu M
    J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
    Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
    Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
    Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
    PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
    Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH
    Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
    Kojima K; Kornblau SM; Ruvolo V; Dilip A; Duvvuri S; Davis RE; Zhang M; Wang Z; Coombes KR; Zhang N; Qiu YH; Burks JK; Kantarjian H; Shacham S; Kauffman M; Andreeff M
    Blood; 2013 May; 121(20):4166-74. PubMed ID: 23564911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.
    Bräutigam K; Biernath-Wüpping J; Bauerschlag DO; von Kaisenberg CS; Jonat W; Maass N; Arnold N; Meinhold-Heerlein I
    J Cancer Res Clin Oncol; 2011 May; 137(5):875-86. PubMed ID: 20878528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
    Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
    Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy.
    Gao W; Lu C; Chen L; Keohavong P
    J Thorac Oncol; 2015 May; 10(5):815-825. PubMed ID: 25629636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.